Literature DB >> 6285815

Effects of moxalactam and cefotaxime on rabbit renal tissue.

F C Luft, G R Aronoff, A P Evan, B A Connors, D K Blase, V H Gattone.   

Abstract

To determine and compare the effects of moxalactam and cefotaxime on kidneys, we gave these drugs in doses of 750 and 1,500 mg/kg to rabbits for 7 days. Cephaloridine was included as a positive control. Neither moxalactam nor cefotaxime at either dose caused lysosomal enzymuria, changes visible by light microscopy or increased plasma creatine. Both drugs caused minor alterations in glomerular ultrastructure at the higher dose. Cephaloridine, on the other hand, caused widespread renal functional and morphological damage. We conclude that in rabbits, both moxalactam and cefotaxime are remarkably nonnephrotoxic.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6285815      PMCID: PMC182020          DOI: 10.1128/AAC.21.5.830

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  5 in total

1.  Enzymuria in gentamicin-induced kidney damage.

Authors:  V Patel; F C Luft; M N Yum; B Patel; W Zeman; S A Kleit
Journal:  Antimicrob Agents Chemother       Date:  1975-03       Impact factor: 5.191

2.  Mechanisms of cephalosporin nephrotoxicity: a comparison of cephaloridine and cephaloglycin.

Authors:  B M Tune; D Fravert
Journal:  Kidney Int       Date:  1980-11       Impact factor: 10.612

3.  Toxicology of cefotaxime in comparison to other cephalosporins.

Authors:  B I Doerr; R Glomot; H Kief; M Kramer; T Sakaguchi
Journal:  J Antimicrob Chemother       Date:  1980-09       Impact factor: 5.790

4.  Comparative activity and beta-lactamase stability of cefoperazone, a piperazine cephalosporin.

Authors:  H C Neu; K P Fu; N Aswapokee; P Aswapokee; K Kung
Journal:  Antimicrob Agents Chemother       Date:  1979-08       Impact factor: 5.191

5.  Effect of gentamicin on glomerular ultrastructure.

Authors:  P S Avasthi; A P Evan; J W Huser; F C Luft
Journal:  J Lab Clin Med       Date:  1981-09
  5 in total
  6 in total

1.  Targeting kidney mesangium by nanoparticles of defined size.

Authors:  Chung Hang J Choi; Jonathan E Zuckerman; Paul Webster; Mark E Davis
Journal:  Proc Natl Acad Sci U S A       Date:  2011-04-04       Impact factor: 11.205

Review 2.  Emerging research and clinical development trends of liposome and lipid nanoparticle drug delivery systems.

Authors:  John C Kraft; Jennifer P Freeling; Ziyao Wang; Rodney J Y Ho
Journal:  J Pharm Sci       Date:  2013-11-25       Impact factor: 3.534

3.  A randomized clinical trial of moxalactam alone versus tobramycin plus clindamycin in abdominal sepsis.

Authors:  J J Schentag; P B Wels; D P Reitberg; P Walczak; J H Van Tyle; R J Lascola
Journal:  Ann Surg       Date:  1983-07       Impact factor: 12.969

Review 4.  Moxalactam (latamoxef). A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.

Authors:  A A Carmine; R N Brogden; R C Heel; J A Romankiewicz; T M Speight; G S Avery
Journal:  Drugs       Date:  1983-10       Impact factor: 9.546

Review 5.  Cefotaxime. A review of its antibacterial activity, pharmacological properties and therapeutic use.

Authors:  A A Carmine; R N Brogden; R C Heel; T M Speight; G S Avery
Journal:  Drugs       Date:  1983-03       Impact factor: 9.546

6.  Nanoparticles Mimicking Viral Cell Recognition Strategies Are Superior Transporters into Mesangial Cells.

Authors:  Sara Maslanka Figueroa; Daniel Fleischmann; Sebastian Beck; Philipp Tauber; Ralph Witzgall; Frank Schweda; Achim Goepferich
Journal:  Adv Sci (Weinh)       Date:  2020-04-22       Impact factor: 16.806

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.